Soligenix, Inc. (SNGX) stock
SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.25−0.03 (-9.88%)
Close on Nov 18, 2026Market cap $5.50MP/E –Yield –
Soligenix revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Soligenix's revenue for the twelve months ending Dec 31, 2024 was $119.37K, down 85.8% year over year. For fiscal 2024 it was $119.37K, down 85.8% from the year before. Over ten years it grew -33.5% a year on average. The highest annual figure on record is $10.45M in fiscal 2016.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $119.37K | -85.8% |
| FY2023 | Dec 31, 2023 | $839.36K | -11.5% |
| FY2022 | Dec 31, 2022 | $948.91K | +15.1% |
| FY2021 | Dec 31, 2021 | $824.27K | -65.1% |
| FY2020 | Dec 31, 2020 | $2.36M | -49.0% |
| FY2019 | Dec 31, 2019 | $4.63M | -11.7% |
| FY2018 | Dec 31, 2018 | $5.24M | -3.5% |
| FY2017 | Dec 31, 2017 | $5.43M | -48.0% |
| FY2016 | Dec 31, 2016 | $10.45M | +19.2% |
| FY2015 | Dec 31, 2015 | $8.77M | +24.5% |
| FY2014 | Dec 31, 2014 | $7.04M | +118.4% |
| FY2013 | Dec 31, 2013 | $3.22M | +2.5% |
| FY2012 | Dec 31, 2012 | $3.14M | -59.0% |
| FY2011 | Dec 31, 2011 | $7.66M | +293.4% |
| FY2010 | Dec 31, 2010 | $1.95M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.34K | -98.9% |
| Q1 FY2024 | Mar 31, 2024 | $117.03K | -54.5% |
| Q4 FY2023 | Dec 31, 2023 | $244.81K | -33.1% |
| Q3 FY2023 | Sep 30, 2023 | $130.44K | -21.5% |
| Q2 FY2023 | Jun 30, 2023 | $206.93K | -9.5% |
| Q1 FY2023 | Mar 31, 2023 | $257.18K | +36.8% |
| Q4 FY2022 | Dec 31, 2022 | $366.07K | +32.8% |
| Q3 FY2022 | Sep 30, 2022 | $166.14K | -10.8% |
| Q2 FY2022 | Jun 30, 2022 | $228.64K | +6.4% |
| Q1 FY2022 | Mar 31, 2022 | $188.06K | +27.4% |
| Q4 FY2021 | Dec 31, 2021 | $275.65K | -14.1% |
| Q3 FY2021 | Sep 30, 2021 | $186.20K | -69.4% |
| Q2 FY2021 | Jun 30, 2021 | $214.82K | -57.5% |
| Q1 FY2021 | Mar 31, 2021 | $147.59K | -84.0% |
| Q4 FY2020 | Dec 31, 2020 | $320.79K | -72.0% |
| Q3 FY2020 | Sep 30, 2020 | $608.81K | -40.0% |
| Q2 FY2020 | Jun 30, 2020 | $505.29K | -63.4% |
| Q1 FY2020 | Mar 31, 2020 | $924.55K | -46.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.14M | +2.2% |
| Q4 FY2018 | Dec 31, 2018 | $1.01M | -21.2% |
| Q3 FY2018 | Sep 30, 2018 | $1.38M | -24.2% |
| Q2 FY2018 | Jun 30, 2018 | $1.73M | +74.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.12M | -15.9% |
| Q4 FY2017 | Dec 31, 2017 | $1.29M | -24.1% |
| Q3 FY2017 | Sep 30, 2017 | $1.82M | -38.4% |
| Q2 FY2017 | Jun 30, 2017 | $990.97K | -68.6% |
| Q1 FY2017 | Mar 31, 2017 | $1.33M | -49.4% |
| Q4 FY2016 | Dec 31, 2016 | $1.70M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.96M | – |
| Q2 FY2016 | Jun 30, 2016 | $3.16M | – |
| Q1 FY2016 | Mar 31, 2016 | $2.63M | – |
See a number that looks wrong?